TMCnet1d
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Bank of New York Mellon Corp Purchases 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Bank of New York Mellon Corp raised its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 18.0% in the fourth quarter, according to the company in its most recent ...
Investing14d
Relay Therapeutics’ SWOT analysis: stock poised for growth amid challenges
Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka inhibitor ...
BizWest15d
OnKure boosts R&D spending with cancer trial underway
“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next quarter, we are ...
Taiwan News15d
OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — ...
Business Insider16d
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)
“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next ...